FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 917 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection MOST POPULAR New on NCI’s Websites for June 2020 June 26, 2020 Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed... January 20, 2025 Discover and translate – a mantra to work by October 17, 2022 Wawa Employee Saves Life Of Customer Who Stopped Breathing After A... January 20, 2022 Load more HOT NEWS Breast Cancer Patients with Low Breast Density May Be More Likely... ScottishPower supports vital research into air pollution and cancer Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival
